Cadila receives USFDA approval to market Pemetrexed for Injection; Stock surges 1%

The drug will be manufactured at the formulation manufacturing facility at Zydus Hospira, Ahmedabad.

Jun 25, 2021 03:06 IST India Infoline News Service

Cadila Healthcare
Zydus Cadila, listed as Cadila Healthcare, on Friday received tentative approval from the USFDA to market Pemetrexed for Injection in the strengths of 100mg/vial, 500 mg/vial, and 1000 mg/vial, single-dose vials (US RLD: Alimta).

As per the regulatory filing, pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

The drug will be manufactured at the formulation manufacturing facility at Zydus Hospira, Ahmedabad.

Zydus Cadila now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY2003-04.

At around 3.11 pm, Cadila was trading at Rs624.10 per piece up by 1.04% on Sensex. 

Related Story

Open Free Demat Account (Rs699)